Investigator Conflicts of Interest
In compliance with federal law, OMRF discloses that the following investigator possesses financial interests that are related to his federally funded research and that could directly and significantly affect the design, conduct or reporting of that research. OMRF has a full management plan in place that provides institutional and independent oversight of the research to ensure that no bias is present.
Rodger McEver, M.D.
Significant Financial Interests
- McEver previously held stock in Selexys Pharmaceuticals, a privately held biotechnology company that was purchased by Novartis AG. Pursuant to that stock purchase agreement, Dr. McEver could receive milestone payments up to a total of $34,796,439.
- McEver also holds stock in Tetherex Pharmaceuticals, a privately held biotechnology company. Based upon the most recent valuation of this company, the value of this stock is believed to be $22,771,122.
Potentially Affected Federal Grants
Dr. McEver is the principal investigator on the following National Institutes of Health grants that could be affected by the financial interests listed above:
- Platelet CLEC-2 Regulation of Vascular Integrity During Inflammation (R01HL128390)
- Signal-dependent neutrophil adhesion to vascular surfaces (R01HL034363)